{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T17:11:37Z","timestamp":1784740297136,"version":"3.55.0"},"update-to":[{"DOI":"10.1016\/j.bbcan.2022.188727","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000}}],"reference-count":191,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.bbcan.2022.188727","type":"journal-article","created":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T15:37:56Z","timestamp":1648827476000},"page":"188727","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["RETRACTED: Coagulation and inflammation in cancer: Limitations and prospects for treatment"],"prefix":"10.1016","volume":"1877","author":[{"given":"Arun Kumar","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishabha","family":"Malviya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.bbcan.2022.188727_bb0005","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.3390\/ijms18081786","article-title":"A review of anti-angiogenic targets for monoclonal antibody cancer therapy","volume":"18","author":"Kong","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bbcan.2022.188727_bb0010","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1146\/annurev-med-060116-022926","article-title":"Molecular and genomic determinants of response to immune checkpoint inhibition in cancer","volume":"69","author":"Jenkins","year":"2018","journal-title":"Annu. Rev. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2022.188727_bb0015","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41577-019-0218-4","article-title":"Tumour-intrinsic resistance to immune checkpoint blockade","volume":"20","author":"Kalbasi","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbcan.2022.188727_bb0020","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ctrv.2017.01.006","article-title":"Immune checkpoint inhibitors and targeted therapies for metastatic melanoma: a network meta-analysis","volume":"54","author":"Pasquali","year":"2017","journal-title":"Cancer Treat. Rev."},{"issue":"3","key":"10.1016\/j.bbcan.2022.188727_bb0025","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001901","article-title":"Considerations for treatment duration in responders to immune checkpoint inhibitors","volume":"9","author":"Marron","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbcan.2022.188727_bb0030","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","article-title":"Management of toxicities of immune checkpoint inhibitors","volume":"44","author":"Spain","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bbcan.2022.188727_bb0035","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1182\/blood.2020007878","article-title":"Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy","volume":"137","author":"Moik","year":"2021","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bbcan.2022.188727_bb0040","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1111\/jth.15272","article-title":"Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors","volume":"19","author":"Icht","year":"2021","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.bbcan.2022.188727_bb0045","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood.2020007338","article-title":"Venous thromboembolism in cancer patients: a population-based cohort study","volume":"137","author":"Mulder","year":"2021","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bbcan.2022.188727_bb0050","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/rth2.12102","article-title":"Managing thrombosis in cancer patients","volume":"2","author":"Wang","year":"2018","journal-title":"Res. Pract. Thromb. Haemost."},{"issue":"Suppl. 2","key":"10.1016\/j.bbcan.2022.188727_bb0055","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/S0049-3848(14)50007-2","article-title":"Risk factors for venous thromboembolism in cancer: novel findings from the Vienna Cancer and Thrombosis Study (CATS)","volume":"133","author":"Konigsbrugge","year":"2014","journal-title":"Thromb. Res."},{"issue":"6","key":"10.1016\/j.bbcan.2022.188727_bb0060","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.3324\/haematol.2018.209114","article-title":"The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis","volume":"104","author":"Mulder","year":"2019","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.bbcan.2022.188727_bb0065","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001719","article-title":"Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival","volume":"9","author":"Sussman","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"4","key":"10.1016\/j.bbcan.2022.188727_bb0070","first-page":"423","article-title":"Increased incidence of venous thromboembolism with cancer immunotherapy","volume":"2","author":"Roopkumar","year":"2021","journal-title":"Med (N Y)"},{"key":"10.1016\/j.bbcan.2022.188727_bb0075","first-page":"98","article-title":"The distribution of secondary growths in cancer of the breast. 1889","volume":"8","author":"Paget","year":"1989","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.bbcan.2022.188727_bb0080","doi-asserted-by":"crossref","DOI":"10.1126\/science.aau6977","article-title":"The biology, function, and biomedical applications of exosomes","volume":"367","author":"Kalluri","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bbcan.2022.188727_bb0085","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41568-018-0006-7","article-title":"A history of exploring cancer in context","volume":"18","author":"Maman","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbcan.2022.188727_bb0090","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2022.188727_bb0095","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.trecan.2018.10.002","article-title":"The multiple layers of the tumor environment","volume":"4","author":"Laplane","year":"2018","journal-title":"Trends Cancer"},{"key":"10.1016\/j.bbcan.2022.188727_bb0100","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1158\/2326-6066.CIR-17-0655","article-title":"IL22 Promotes Kras-Mutant lung cancer by induction of a protumor immune response and protection of stemness properties","volume":"6","author":"Khosravi","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.bbcan.2022.188727_bb0105","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature07205","article-title":"Cancer-related inflammation","volume":"454","author":"Mantovani","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2022.188727_bb0110","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s12307-009-0025-8","article-title":"The tumor microenvironment: the making of a paradigm","volume":"2","author":"Witz","year":"2009","journal-title":"Cancer Microenviron."},{"key":"10.1016\/j.bbcan.2022.188727_bb0115","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/35094059","article-title":"Putting tumours in context","volume":"1","author":"Bissell","year":"2001","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbcan.2022.188727_bb0120","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41568-018-0006-7","article-title":"A history of exploring cancer in context","volume":"18","author":"Maman","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbcan.2022.188727_bb0125","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.ccell.2019.04.001","article-title":"The fire within: cell-autonomous mechanisms in inflammation-driven cancer","volume":"35","author":"Todoric","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2022.188727_bb0130","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.3389\/fonc.2019.01556","article-title":"Understanding the complexity of the tumor microenvironment in K-ras mutant lung cancer: finding an alternative path to prevention and treatment","volume":"9","author":"Deng","year":"2019","journal-title":"Front. Oncol."},{"issue":"Suppl. 1","key":"10.1016\/j.bbcan.2022.188727_bb0135","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/S0049-3848(15)50432-5","article-title":"The mechanisms of cancer-associated thrombosis","volume":"135","author":"Falanga","year":"2015","journal-title":"Thromb. Res."},{"issue":"6","key":"10.1016\/j.bbcan.2022.188727_bb0140","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1111\/j.1538-7836.2004.00721.x","article-title":"Screening for occult cancer in patients with acute deep vein thrombosis or pulmonary embolism","volume":"2","author":"Monreal","year":"2004","journal-title":"J. Thromb. Haemost."},{"issue":"Suppl. 2","key":"10.1016\/j.bbcan.2022.188727_bb0145","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/S0049-3848(07)70125-1","article-title":"Tissue factor and PAR signaling in tumor progression","volume":"120","author":"Ruf","year":"2007","journal-title":"Thromb. Res."},{"issue":"04","key":"10.1016\/j.bbcan.2022.188727_bb0150","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1055\/s-0039-1687895","article-title":"Role of tissue factor in tumor progression and cancer-associated thrombosis","volume":"45","author":"Rondon","year":"2019","journal-title":"Semin. Thromb. Hemost."},{"issue":"11","key":"10.1016\/j.bbcan.2022.188727_bb0155","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1055\/s-0037-1616053","article-title":"Role of protease-activated receptor 1 in tumor metastasis promoted by tissue factor","volume":"86","author":"Bromberg","year":"2001","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.bbcan.2022.188727_bb0160","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3892\/ol.2011.291","article-title":"Protease-activated receptors in cancer: a systematic review","volume":"2","author":"Han","year":"2011","journal-title":"Oncol. Lett."},{"issue":"Suppl. 1","key":"10.1016\/j.bbcan.2022.188727_bb0165","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/S0049-3848(13)70024-0","article-title":"Mechanisms of thrombosis in cancer","volume":"131","author":"Falanga","year":"2013","journal-title":"Thromb. Res."},{"key":"10.1016\/j.bbcan.2022.188727_bb0170","doi-asserted-by":"crossref","first-page":"5271","DOI":"10.1182\/blood-2008-01-078204","article-title":"The vessel wall and its interactions","volume":"111","author":"Wagner","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2022.188727_bb0175","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1182\/blood-2014-08-595686","article-title":"von Willebrand factor fibers promote cancer-associated platelet aggregation in malignant melanoma of mice and humans","volume":"125","author":"Bauer","year":"2015","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.bbcan.2022.188727_bb0180","doi-asserted-by":"crossref","first-page":"7899","DOI":"10.1073\/pnas.0608422104","article-title":"Shear-induced unfolding triggers adhesion of von Willebrand factor fibers","volume":"104","author":"Schneider","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbcan.2022.188727_bb0185","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1182\/blood-2008-02-142422","article-title":"High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS)","volume":"112","author":"Ay","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2022.188727_bb0190","first-page":"1","article-title":"Low-molecular-weight heparins and cancer: focus on antitumoral effect","author":"Franchini","year":"2015","journal-title":"Ann. Med."},{"issue":"42","key":"10.1016\/j.bbcan.2022.188727_bb0195","doi-asserted-by":"crossref","first-page":"68527","DOI":"10.18632\/oncotarget.11832","article-title":"Heparins that block VEGF-A-mediated von Willebrand factor fiber generation are potent inhibitors of hematogenous but not lymphatic metastasis","volume":"7","author":"Goertz","year":"2016","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.bbcan.2022.188727_bb0200","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/ijc.30498","article-title":"d-Dimers in malignant melanoma: association with prognosis and dynamic variation in disease progress","volume":"140","author":"Desch","year":"2017","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbcan.2022.188727_bb0205","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12916-016-0623-5","article-title":"Cancer immunotherapy: the beginning of the end of cancer?","volume":"14","author":"Farkona","year":"2016","journal-title":"BMC Med."},{"key":"10.1016\/j.bbcan.2022.188727_bb0210","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejca.2017.01.035","article-title":"Cancer immunotherapy: opportunities and challenges in the rapidly evolving clinical landscape","volume":"81","author":"Emens","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bbcan.2022.188727_bb0215","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1158\/1078-0432.CCR-12-1972","article-title":"Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy","volume":"19","author":"Nirschl","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2022.188727_bb0220","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12916-016-0623-5","article-title":"Cancer immunotherapy: the beginning of the end of cancer?","volume":"14","author":"Farkona","year":"2016","journal-title":"BMC Med."},{"key":"10.1016\/j.bbcan.2022.188727_bb0225","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2022.188727_bb0230","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2022.188727_bb0235","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.semcancer.2012.02.003","article-title":"Melanoma-induced immunosuppression and its neutralization","volume":"22","author":"Umansky","year":"2012","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bbcan.2022.188727_bb0240","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","article-title":"The nature of myeloid-derived suppressor cells in the tumor microenvironment","volume":"37","author":"Kumar","year":"2016","journal-title":"Trends Immunol."},{"key":"10.1016\/j.bbcan.2022.188727_bb0245","doi-asserted-by":"crossref","first-page":"422","DOI":"10.4049\/jimmunol.1701019","article-title":"Myeloid-derived suppressor cells: immune-suppressive cells that impair antitumor immunity and are sculpted by their environment","volume":"200","author":"Ostrand-Rosenberg","year":"2018","journal-title":"J. Immunol."},{"key":"10.1016\/j.bbcan.2022.188727_bb0250","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.coi.2018.03.009","article-title":"Plasticity of myeloid-derived suppressor cells in cancer","volume":"51","author":"Tcyganov","year":"2018","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.bbcan.2022.188727_bb0255","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1007\/s00262-015-1766-5","article-title":"Immunological factors influencing clinical outcome in lung cancer patients after telomerase peptide vaccination","volume":"64","author":"Hansen","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.bbcan.2022.188727_bb0260","doi-asserted-by":"crossref","first-page":"5241","DOI":"10.1158\/0008-5472.CAN-15-3164","article-title":"Accumulation of MDSC and Th17 cells in patients with metastatic colorectal cancer predicts the efficacy of a FOLFOX\u2013bevacizumab drug treatment regimen","volume":"76","author":"Limagne","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2022.188727_bb0265","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1189\/jlb.5VMR1116-458RRR","article-title":"Myeloid-derived suppressor cells\u2014a new therapeutic target to overcome resistance to cancer immunotherapy","volume":"102","author":"Chesney","year":"2017","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.bbcan.2022.188727_bb0270","doi-asserted-by":"crossref","first-page":"5453","DOI":"10.1158\/1078-0432.CCR-15-0676","article-title":"Myeloid cells and related chronic inflammatory factors as novel predictive markers in melanoma treatment with ipilimumab","volume":"21","author":"Gebhardt","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2022.188727_bb0275","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1182\/blood.V100.3.854","article-title":"Evaluation of role of GCSF in the production, survival, and release of neutrophils from bone marrow into circulation","volume":"100","author":"Basu","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2022.188727_bb0280","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/imcb.12028","article-title":"Homeostatic control of dendritic cell numbers and differentiation","volume":"96","author":"Dress","year":"2018","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.bbcan.2022.188727_bb0285","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nri3399","article-title":"Neutrophil recruitment and function in health and inflammation","volume":"13","author":"Kolaczkowska","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbcan.2022.188727_bb0290","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.immuni.2019.01.019","article-title":"Emerging principles in myelopoiesis at homeostasis and during infection and inflammation","volume":"50","author":"Schultze","year":"2019","journal-title":"Immunity."},{"key":"10.1016\/j.bbcan.2022.188727_bb0295","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1172\/JCI108517","article-title":"Neutrophil kinetics in man","volume":"58","author":"Dancey","year":"1976","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.bbcan.2022.188727_bb0300","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.stem.2014.01.007","article-title":"Conversion of danger signals into cytokine signals by hematopoietic stem and progenitor cells for regulation of stress-induced hematopoiesis","volume":"14","author":"Zhao","year":"2014","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.bbcan.2022.188727_bb0305","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/nri3660","article-title":"Emergency granulopoiesis","volume":"14","author":"Manz","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbcan.2022.188727_bb0310","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nri3175","article-title":"Coordinated regulation of myeloid cells by tumours","volume":"12","author":"Gabrilovich","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbcan.2022.188727_bb0315","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2022.188727_bb0320","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s10555-010-9223-6","article-title":"Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity","volume":"29","author":"DeNardo","year":"2010","journal-title":"Cancer Metas. Rev."},{"key":"10.1016\/j.bbcan.2022.188727_bb0325","doi-asserted-by":"crossref","first-page":"6337","DOI":"10.1158\/0008-5472.CAN-04-0757","article-title":"Highdose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells","volume":"64","author":"Serafini","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2022.188727_bb0330","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/nrc1782","article-title":"Paradoxical roles of the immune system during cancer development","volume":"6","author":"de Visser","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbcan.2022.188727_bb0335","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/nm.2753","article-title":"Melanoma exosomes educate bone marrow progenitorcells toward a pro-metastatic phenotype through MET","volume":"18","author":"Peinado","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbcan.2022.188727_bb0340","doi-asserted-by":"crossref","first-page":"4221","DOI":"10.1073\/pnas.1320753111","article-title":"Circulating hematopoietic stem and progenitor cells are myeloidbiased in cancer patients","volume":"111","author":"Wu","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbcan.2022.188727_bb0345","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/eji.200939903","article-title":"Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF","volume":"40","author":"Dolcetti","year":"2010","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.bbcan.2022.188727_bb0350","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.immuni.2010.05.010","article-title":"Tumor-induced tolerance and immune suppression depend on the C\/EBPbeta transcription factor","volume":"32","author":"Marigo","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.bbcan.2022.188727_bb0355","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ccell.2015.07.006","article-title":"RORC1 regulates tumor-promoting \u201cemergency\u201d granulo-monocytopoiesis","volume":"28","author":"Strauss","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2022.188727_bb0360","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.ccr.2012.04.025","article-title":"Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer","volume":"21","author":"Bayne","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2022.188727_bb0365","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/jso.24523","article-title":"The prognostic value of neutrophil-to-lymphocyte ratio in colorectal cancer: a systematic review","volume":"115","author":"Haram","year":"2017","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.bbcan.2022.188727_bb0370","doi-asserted-by":"crossref","first-page":"22089","DOI":"10.1038\/srep22089","article-title":"Prognostic significance of neutrophil-to-lymphocyte ratio in prostate cancer: evidence from 16,266 patients","volume":"6","author":"Gu","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbcan.2022.188727_bb0375","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1001\/archinte.158.6.585","article-title":"Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study","volume":"158","author":"Silverstein","year":"1998","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.bbcan.2022.188727_bb0380","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1200\/JCO.2006.07.4393","article-title":"Incidence of venous thromboembolism and the impact on survival in breast cancer patients","volume":"25","author":"Chew","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2022.188727_bb0385","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJMoa040766","article-title":"Circulating tumor cells, disease progression, and survival in metastatic breast cancer","volume":"351","author":"Cristofanilli","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2022.188727_bb0390","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S1470-2045(12)70209-7","article-title":"Circulating tumour cells in non-metastatic breast cancer: a prospective study","volume":"13","author":"Lucci","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2022.188727_bb0395","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/nrclinonc.2010.171","article-title":"Molecular mechanisms of metastasis in breast cancer-clinical applications","volume":"7","author":"Mego","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2022.188727_bb0400","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1038\/sj.bjc.6605413","article-title":"Circulating tumour cells are associated with increased risk of venous thromboembolism in metastatic breast cancer patients","volume":"101","author":"Mego","year":"2009","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbcan.2022.188727_bb0405","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1038\/sj.bjc.6604620","article-title":"Early changes in the haemostatic and procoagulant systems after chemotherapy for breast cancer","volume":"99","author":"Kirwan","year":"2008","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbcan.2022.188727_bb0410","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ctrv.2007.10.005","article-title":"Evolving role of uPA\/ uPAR system in human cancers","volume":"34","author":"Dass","year":"2008","journal-title":"Cancer Treat. Rev."},{"issue":"4","key":"10.1016\/j.bbcan.2022.188727_bb0415","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.thromres.2013.01.015","article-title":"von Willebrand factor and cancer: a renewed interest","volume":"131","author":"Franchini","year":"2013","journal-title":"Thromb. Res."},{"issue":"18","key":"10.1016\/j.bbcan.2022.188727_bb0420","doi-asserted-by":"crossref","first-page":"5302","DOI":"10.1158\/0008-5472.CAN-16-0784","article-title":"Monocyte induction of E-selectin-mediated endothelial activation releases VECadherin junctions to promote tumor cell extravasation in the metastasis cascade","volume":"76","author":"Hauselmann","year":"2016","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.bbcan.2022.188727_bb0425","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.semcancer.2010.04.005","article-title":"Selectins promote tumor metastasis","volume":"20","author":"Laubli","year":"2010","journal-title":"Semin. Cancer Biol."},{"issue":"02","key":"10.1016\/j.bbcan.2022.188727_bb0430","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1055\/s-0037-1613434","article-title":"Molecular mechanisms of leukocyte recruitment: organ-specific mechanisms of action","volume":"89","author":"Liu","year":"2003","journal-title":"Thromb. Haemost."},{"issue":"04","key":"10.1016\/j.bbcan.2022.188727_bb0435","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1160\/TH13-09-0800","article-title":"The various states of von Willebrand factor and their function in physiology and pathophysiology","volume":"111","author":"Huck","year":"2014","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.bbcan.2022.188727_bb0440","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1182\/blood-2006-03-010322","article-title":"P-selectin glycoprotein ligand 1 and beta2-integrins cooperate in the adhesion of leukocytes to von Willebrand factor","volume":"108","author":"Pendu","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2022.188727_bb0445","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1182\/blood-2010-03-276311","article-title":"von Willebrand factor promotes leukocyte extravasation","volume":"116","author":"Petri","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2022.188727_bb0450","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1084\/jem.20112322","article-title":"Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo","volume":"209","author":"von Bruhl","year":"2012","journal-title":"J. Exp. Med."},{"issue":"7582","key":"10.1016\/j.bbcan.2022.188727_bb0455","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nature16140","article-title":"Neutrophils support lung colonization of metastasisinitiating breast cancer cells","volume":"528","author":"Wculek","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2022.188727_bb0460","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/701067","article-title":"Distinct functions of neutrophil in cancer and its regulation","volume":"2015","author":"Granot","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.bbcan.2022.188727_bb0465","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11040564","article-title":"Tumor-associated neutrophils in cancer: going pro","volume":"11","author":"Wu","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.bbcan.2022.188727_bb0470","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2019\/8968943","article-title":"Orchestration of adaptive T cell responses by neutrophil granule contents","volume":"2019","author":"Minns","year":"2019","journal-title":"Mediat. Inflamm."},{"issue":"8","key":"10.1016\/j.bbcan.2022.188727_bb0475","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1172\/JCI67484","article-title":"Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis","volume":"123","author":"Cools-Lartigue","year":"2013","journal-title":"J. Clin. Invest."},{"issue":"8","key":"10.1016\/j.bbcan.2022.188727_bb0480","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/nm.2184","article-title":"Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases","volume":"16","author":"Massberg","year":"2010","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.bbcan.2022.188727_bb0485","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.2020005861","article-title":"Neutrophil extracellular traps promote fibrous vascular occlusions in chronic thrombosis","volume":"137","author":"Sharma","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2022.188727_bb0490","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1182\/blood-2016-09-741298","article-title":"Platelets and neutrophil extracellular traps collaborate to promote intravascular coagulation during sepsis in mice","volume":"129","author":"McDonald","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2022.188727_bb0495","doi-asserted-by":"crossref","DOI":"10.3390\/cells8090946","article-title":"Prognostic role of blood NETosis in the progression of head and neck cancer","volume":"8","author":"Decker","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.bbcan.2022.188727_bb0500","article-title":"Primary tumors induce neutrophil extracellular traps with targetable metastasis promoting effects","volume":"5","author":"Rayes","year":"2019","journal-title":"JCI Insight"},{"issue":"15","key":"10.1016\/j.bbcan.2022.188727_bb0505","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1158\/0008-5472.CAN-15-3051","article-title":"Tumor-induced NETosis as a risk factor for metastasis and organ failure","volume":"76","author":"Cedervall","year":"2016","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.bbcan.2022.188727_bb0510","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1161\/ATVBAHA.119.312463","article-title":"Neutrophil extracellular traps: villains and targets in arterial, venous, and cancer-associated thrombosis","volume":"39","author":"Th\u00e5lin","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"1","key":"10.1016\/j.bbcan.2022.188727_bb0515","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nri3345","article-title":"Thrombosis as an intravascular effector of innate immunity","volume":"13","author":"Engelmann","year":"2013","journal-title":"Nat. Rev. Immunol."},{"issue":"12","key":"10.1016\/j.bbcan.2022.188727_bb0520","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/ni.3858","article-title":"Novel mechanisms and functions of complement","volume":"18","author":"Hajishengallis","year":"2017","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.bbcan.2022.188727_bb0525","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00281-011-0280-x","article-title":"Interactions between coagulation and complement\u2013their role in inflammation","volume":"34","author":"Oikonomopoulou","year":"2012","journal-title":"Semin. Immunopathol."},{"issue":"1","key":"10.1016\/j.bbcan.2022.188727_bb0530","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00281-017-0644-y","article-title":"Complement as a regulator of adaptive immunity","volume":"40","author":"Killick","year":"2018","journal-title":"Semin. Immunopathol."},{"issue":"9","key":"10.1016\/j.bbcan.2022.188727_bb0535","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1161\/CIRCRESAHA.116.306853","article-title":"Cross talk pathways between coagulation and inflammation","volume":"118","author":"Foley","year":"2016","journal-title":"Circ. Res."},{"issue":"12","key":"10.1016\/j.bbcan.2022.188727_bb0540","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/s41568-019-0210-0","article-title":"Context-dependent roles of complement in cancer","volume":"19","author":"Roumenina","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbcan.2022.188727_bb0545","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1182\/blood-2016-11-749879","article-title":"Distinct contributions of complement factors to platelet activation and fibrin formation in venous thrombus development","volume":"129","author":"Subramaniam","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bbcan.2022.188727_bb0550","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.4049\/jimmunol.1601121","article-title":"Interaction between multimeric von willebrand factor and complement: a fresh look to the pathophysiology of microvascular thrombosis","volume":"199","author":"Bettoni","year":"2017","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.bbcan.2022.188727_bb0555","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nm1419","article-title":"Generation of C5a in the absence of C3: a new complement activation pathway","volume":"12","author":"Huber-Lang","year":"2006","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.bbcan.2022.188727_bb0560","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.4049\/jimmunol.177.7.4794","article-title":"A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways","volume":"177","author":"Ritis","year":"2006","journal-title":"J. Immunol."},{"issue":"02","key":"10.1016\/j.bbcan.2022.188727_bb0565","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1055\/s-0038-1655974","article-title":"C5a induces tissue factor activity on endothelial cells","volume":"77","author":"Ikeda","year":"1997","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.bbcan.2022.188727_bb0570","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jneuroim.2014.11.016","article-title":"Complement activation in Glioblastoma multiforme pathophysiology: evidence from serum levels and presence of complement activation products in tumor tissue","volume":"278","author":"Bouwens","year":"2015","journal-title":"J. Neuroimmunol."},{"issue":"5","key":"10.1016\/j.bbcan.2022.188727_bb0575","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/sj.bjc.6602334","article-title":"Ascitic complement system in ovarian cancer","volume":"92","author":"Bj\u00f8rge","year":"2005","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbcan.2022.188727_bb0580","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/jnci\/djt205","article-title":"Investigation of complement activation product c4d as a diagnostic and prognostic biomarker for lung cancer","volume":"105","author":"Ajona","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"issue":"7","key":"10.1016\/j.bbcan.2022.188727_bb0585","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.humimm.2008.05.005","article-title":"Pre- and postoperative levels in serum of mannan-binding lectin associated serine protease-2 -a prognostic marker in colorectal cancer","volume":"69","author":"Ytting","year":"2008","journal-title":"Hum. Immunol."},{"issue":"1","key":"10.1016\/j.bbcan.2022.188727_bb0590","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11037","article-title":"Coagulation induced by C3aR-dependent NETosis drives protumorigenic neutrophils during small intestinal tumorigenesis","volume":"7","author":"Guglietta","year":"2016","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.bbcan.2022.188727_bb0595","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1158\/2159-8290.CD-16-1184","article-title":"A combined PD-1\/C5a blockade synergistically protects against lung cancer growth and metastasis","volume":"7","author":"Ajona","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbcan.2022.188727_bb0600","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3389\/fonc.2018.00088","article-title":"Brain metastases in oncogene-addicted non-small cell lung cancer patients: incidence and treatment","volume":"8","author":"Remon","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2022.188727_bb0605","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ctrv.2016.12.006","article-title":"Leptomeningeal carcinomatosis in non-small cell lung cancer patients: a continuing challenge in the personalized treatment era","volume":"53","author":"Remon","year":"2017","journal-title":"Cancer Treat. Rev."},{"issue":"5","key":"10.1016\/j.bbcan.2022.188727_bb0610","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.jtho.2019.01.007","article-title":"Clinical utility of cerebrospinal fluid cell-free DNA as liquid biopsy for leptomeningeal metastases in ALK-rearranged NSCLC","volume":"14","author":"Zheng","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bbcan.2022.188727_bb0615","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/cncr.24877","article-title":"Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall-cell lung cancer","volume":"116","author":"Lee","year":"2010","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.bbcan.2022.188727_bb0620","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/annonc\/mdz080","article-title":"Molecular screening program to select molecularbased recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial","volume":"30","author":"Tredan","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbcan.2022.188727_bb0625","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.jtho.2018.05.030","article-title":"Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC","volume":"13","author":"Rolfo","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bbcan.2022.188727_bb0630","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jtho.2017.12.001","volume":"13","author":"Lindeman","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bbcan.2022.188727_bb0635","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00211","article-title":"Real-world utility of an amplicon-based next generation sequencing liquid biopsy for broad molecular profiling in patients with advanced non\u2013small-cell lung cancer","author":"Remon","year":"2019","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.bbcan.2022.188727_bb0640","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/annonc\/mdy009","article-title":"Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy","volume":"29","author":"Li","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbcan.2022.188727_bb0645","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/annonc\/mdy544","article-title":"Cerebrospinal fluid cell-free tumour DNA as a liquid biopsy for primary brain tumours and central nervous system metastases","volume":"30","author":"Seoane","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbcan.2022.188727_bb0650","doi-asserted-by":"crossref","first-page":"8839","DOI":"10.1038\/ncomms9839","article-title":"Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma","volume":"6","author":"De Mattos-Arruda","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2022.188727_bb0655","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ejca.2017.11.018","article-title":"Arterial thrombosis and anti-PD-1 blockade","volume":"91","author":"Boutros","year":"2018","journal-title":"Eur. J. Cancer"},{"issue":"10","key":"10.1016\/j.bbcan.2022.188727_bb0660","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.7150\/thno.18588","article-title":"Circulating tumor cells: moving biological insights into detection","volume":"7","author":"Chen","year":"2017","journal-title":"Theranostics."},{"issue":"9","key":"10.1016\/j.bbcan.2022.188727_bb0665","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nrclinonc.2017.14","article-title":"Integrating liquid biopsies into the management of cancer","volume":"14","author":"Siravegna","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2022.188727_bb0670","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1039\/C3LC50644D","article-title":"Technologies for detection of circulating tumor cells: facts and vision","volume":"14","author":"Alix-Panabi\u00e8res","year":"2014","journal-title":"Lab Chip"},{"issue":"3","key":"10.1016\/j.bbcan.2022.188727_bb0675","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.molonc.2015.12.002","article-title":"Challenges in circulating tumor cell detection by the CellSearch system","volume":"10","author":"Andree","year":"2016","journal-title":"Mol. Oncol."},{"issue":"3","key":"10.1016\/j.bbcan.2022.188727_bb0680","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.path.2018.04.008","article-title":"Circulating tumor cells: applications in cytopathology","volume":"11","author":"Lowe","year":"2018","journal-title":"Surg. Pathol. Clin."},{"issue":"2","key":"10.1016\/j.bbcan.2022.188727_bb0685","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1373\/clinchem.2015.242537","article-title":"Functional studies on viable circulating tumor cells","volume":"62","author":"Pantel","year":"2016","journal-title":"Clin. Chem."},{"issue":"2","key":"10.1016\/j.bbcan.2022.188727_bb0690","first-page":"8","article-title":"Circulating tumor cell analysis in preclinical mousemodels of metastasis","volume":"8","author":"Kitz","year":"2018","journal-title":"Diagnostics (Basel)"},{"issue":"10","key":"10.1016\/j.bbcan.2022.188727_bb0695","doi-asserted-by":"crossref","first-page":"815","DOI":"10.18632\/oncoscience.195","article-title":"Cell lines from circulating tumor cells","volume":"2","author":"Pantel","year":"2015","journal-title":"Oncoscience"},{"issue":"12","key":"10.1016\/j.bbcan.2022.188727_bb0700","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1158\/0008-5472.CAN-15-0145","article-title":"Ex vivo culture of ctcs: an emerging resource to guide cancer therapy","volume":"75","author":"Maheswaran","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2022.188727_bb0705","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1182\/blood-2007-06-095646","article-title":"Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria","volume":"110","author":"Hillmen","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bbcan.2022.188727_bb0710","article-title":"Mechanisms underlying low-clinical responses to PD-1\/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1","volume":"9","author":"Yin Zi","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbcan.2022.188727_bb0715","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00168","article-title":"Cold tumors: a therapeutic challenge for immunotherapy","author":"Bonaventura","year":"2019","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.bbcan.2022.188727_bb0720","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1002\/eji.201847645","article-title":"Trousseau\u2019s syndrome triggered by an immune checkpoint blockade in a nonsmall cell lung cancer patient","volume":"48","author":"Horio","year":"2018","journal-title":"Eur. J. Immunol."},{"issue":"3","key":"10.1016\/j.bbcan.2022.188727_bb0725","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1159\/000492463","article-title":"Thromboembolic events related to treatment with checkpoint inhibitors: report of two cases","volume":"11","author":"Tsukamoto","year":"2018","journal-title":"Case Rep. Oncol."},{"issue":"6","key":"10.1016\/j.bbcan.2022.188727_bb0730","doi-asserted-by":"crossref","first-page":"762","DOI":"10.3390\/jcm8060762","article-title":"Disorder of coagulation-fibrinolysis system: an emerging toxicity of anti-PD-1\/PD-L1 monoclonal antibodies","volume":"8","author":"Sato","year":"2019","journal-title":"J. Clin. Med."},{"issue":"4","key":"10.1016\/j.bbcan.2022.188727_bb0735","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/hon.2743","article-title":"Hematological toxicities in immune checkpoint inhibitors: a pharmacovigilance study from 2014 to 2019","volume":"38","author":"Ye","year":"2020","journal-title":"Hematol. Oncol."},{"issue":"13","key":"10.1016\/j.bbcan.2022.188727_bb0740","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1158\/0008-5472.CAN-18-3206","article-title":"Thrombin signaling promotes pancreatic adenocarcinoma through PAR-1- dependent immune evasion","volume":"79","author":"Yang","year":"2019","journal-title":"Cancer Res."},{"issue":"39","key":"10.1016\/j.bbcan.2022.188727_bb0745","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aaw8405","article-title":"Myeloid cellsynthesized coagulation factor X dampens antitumor immunity","volume":"4","author":"Graf","year":"2019","journal-title":"Sci. Immunol."},{"issue":"6817","key":"10.1016\/j.bbcan.2022.188727_bb0750","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/35051688","article-title":"Cardiovascular biology. Small cells, big issues","volume":"409","author":"Brass","year":"2001","journal-title":"Nature"},{"issue":"44","key":"10.1016\/j.bbcan.2022.188727_bb0755","doi-asserted-by":"crossref","first-page":"27460","DOI":"10.18632\/oncotarget.25446","article-title":"PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy","volume":"9","author":"Rolfes","year":"2018","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.bbcan.2022.188727_bb0760","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.4049\/jimmunol.1601708","article-title":"Binding of platelets to lymphocytes: a potential anti-inflammatory therapy in rheumatoid arthritis","volume":"198","author":"Zamora","year":"2017","journal-title":"J. Immunol."},{"key":"10.1016\/j.bbcan.2022.188727_bb0765","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay4860","article-title":"Thrombin contributes to cancer immune evasion via proteolysis of platelet-bound GARP to activate LTGF-beta","volume":"12","author":"Metelli","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bbcan.2022.188727_bb0770","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10060194","article-title":"TGF-beta in T cell biology: implications for cancer immunotherapy","volume":"10","author":"Dahmani","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.bbcan.2022.188727_bb0775","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aai7911","article-title":"Platelets subvert T cell immunity against cancer via GARP-TGFbeta axis","volume":"2","author":"Rachidi","year":"2017","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.bbcan.2022.188727_bb0780","doi-asserted-by":"crossref","first-page":"7775","DOI":"10.1158\/0008-5472.CAN-09-2123","article-title":"Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity","volume":"69","author":"Kopp","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2022.188727_bb0785","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ccr.2005.10.012","article-title":"TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance","volume":"8","author":"Thomas","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2022.188727_bb0790","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1158\/1078-0432.CCR-17-2653","article-title":"Phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGFbeta, in advanced solid tumors","volume":"24","author":"Strauss","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2022.188727_bb0795","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000433","article-title":"Dual targeting of TGF-beta and PD-L1 via a bifunctional anti-PD-L1\/TGF-betaRII agent: status of preclinical and clinical advances","volume":"8","author":"Lind","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.bbcan.2022.188727_bb0800","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00441-017-2727-4","article-title":"Platelet-neutrophil interactions as drivers of inflammatory and thrombotic disease","volume":"371","author":"Lisman","year":"2018","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.bbcan.2022.188727_bb0805","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nature14282","article-title":"IL-17- producing gammadelta T cells and neutrophils conspire to promote breast cancer metastasis","volume":"522","author":"Coffelt","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2022.188727_bb0810","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2022.188727_bb0815","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbcan.2022.188727_bb0820","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.4161\/onci.21335","article-title":"Targeting PD-1\/PD-L1 interactions for cancer immunotherapy","volume":"1","author":"Zitvogel","year":"2012","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.bbcan.2022.188727_bb0825","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/cam4.106","article-title":"PD-1 as a potential target in cancer therapy","volume":"2","author":"McDermott","year":"2013","journal-title":"Cancer Med."},{"key":"10.1016\/j.bbcan.2022.188727_bb0830","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0072249","article-title":"IFN-gamma-stimulated neutrophils suppress lymphocyte proliferation through expression of PD-L1","volume":"8","author":"de Kleijn","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.bbcan.2022.188727_bb0835","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.ccell.2016.04.014","article-title":"CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma","volume":"29","author":"Steele","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2022.188727_bb0840","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju124","article-title":"Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis","volume":"106","author":"Templeton","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"issue":"24","key":"10.1016\/j.bbcan.2022.188727_bb0845","doi-asserted-by":"crossref","first-page":"5453","DOI":"10.1158\/1078-0432.CCR-15-0676","article-title":"Myeloid cells and related chronic inflammatory factors as novel predictive markers in melanoma treatment with ipilimumab","volume":"21","author":"Gebhardt","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.bbcan.2022.188727_bb0850","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.immuni.2017.09.012","article-title":"Reactive neutrophil responses dependent on the receptor tyrosine kinase c-MET limit cancer immunotherapy","volume":"47","author":"Glodde","year":"2017","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.bbcan.2022.188727_bb0855","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s40264-018-0780-x","article-title":"Safety and tolerability of c-MET inhibitors in cancer","volume":"42","author":"Puccini","year":"2019","journal-title":"Drug Saf."},{"key":"10.1016\/j.bbcan.2022.188727_bb0860","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3389\/fimmu.2015.00262","article-title":"Complement system part I - molecular mechanisms of activation and regulation","volume":"6","author":"Merle","year":"2015","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.bbcan.2022.188727_bb0865","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41577-019-0168-x","article-title":"New insights into the immune functions of complement","volume":"19","author":"Reis","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbcan.2022.188727_bb0870","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1373\/clinchem.2015.251314","article-title":"Complement C3 and high risk of venous thromboembolism: 80517 individuals from the Copenhagen general population study","volume":"62","author":"Norgaard","year":"2016","journal-title":"Clin. Chem."},{"issue":"11","key":"10.1016\/j.bbcan.2022.188727_bb0875","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/ni.1655","article-title":"Modulation of the antitumor immune response by complement","volume":"9","author":"Markiewski","year":"2008","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bbcan.2022.188727_bb0880","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1172\/JCI90962","article-title":"The role of the complement system in cancer","volume":"127","author":"Afshar-Kharghan","year":"2017","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbcan.2022.188727_bb0885","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/ajh.24278","article-title":"Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study","volume":"91","author":"Loschi","year":"2016","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bbcan.2022.188727_bb0890","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1182\/blood-2014-09-600411","article-title":"Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS","volume":"125","author":"Cofiell","year":"2015","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.bbcan.2022.188727_bb0895","doi-asserted-by":"crossref","first-page":"9188","DOI":"10.1073\/pnas.87.23.9188","article-title":"Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum","volume":"87","author":"Shak","year":"1990","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbcan.2022.188727_bb0900","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3389\/fimmu.2016.00373","article-title":"NETosis in cancer - platelet-neutrophil crosstalk promotes tumor-associated pathology","volume":"7","author":"Olsson","year":"2016","journal-title":"Front. Immunol."},{"issue":"13","key":"10.1016\/j.bbcan.2022.188727_bb0905","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1158\/0008-5472.CAN-14-3299","article-title":"Neutrophil extracellular traps accumulate in peripheral blood vessels and compromise organ function in tumor-bearing animals","volume":"75","author":"Cedervall","year":"2015","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.bbcan.2022.188727_bb0910","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura","volume":"380","author":"Scully","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2022.188727_bb0915","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood-2017-06-788026","article-title":"Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura","volume":"130","author":"Scully","year":"2017","journal-title":"Blood"},{"issue":"Suppl. 2","key":"10.1016\/j.bbcan.2022.188727_bb0920","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1016\/S0049-3848(10)70017-7","article-title":"Antimetastatic activities of heparins and modified heparins. Experimental evidence","volume":"125","author":"Borsig","year":"2010","journal-title":"Thromb. Res."},{"issue":"36","key":"10.1016\/j.bbcan.2022.188727_bb0925","doi-asserted-by":"crossref","first-page":"15880","DOI":"10.1073\/pnas.1005743107","article-title":"Extracellular DNA traps promote thrombosis","volume":"107","author":"Fuchs","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7","key":"10.1016\/j.bbcan.2022.188727_bb0930","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41571-019-0187-3","article-title":"Liquid biopsy and minimal residual disease - latest advances and implications for cure","volume":"16","author":"Pantel","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.bbcan.2022.188727_bb0935","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41568-019-0180-2","article-title":"Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells","volume":"19","author":"Keller","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbcan.2022.188727_bb0940","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1742-4682-8-35","article-title":"Relational grounding facilitates development of scientifically useful multiscale models","volume":"8","author":"Hunt","year":"2011","journal-title":"Theo Biol. Med. Mod."},{"key":"10.1016\/j.bbcan.2022.188727_bb0945","series-title":"Liver Pathophysiology","first-page":"113","article-title":"Liver regeneration","author":"Katoonizadeh","year":"2017"},{"key":"10.1016\/j.bbcan.2022.188727_bb0950","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1042\/bj2540411","article-title":"Glutathione replenishment capacity is lower in isolated perivenous than in periportal hepatocytes","volume":"254","author":"Kera","year":"1988","journal-title":"Biochem. J."},{"key":"10.1016\/j.bbcan.2022.188727_bb0955","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/wsbm.1270","article-title":"Tuneable resolution as a systems biology approach for multi-scale, multi-compartment computational models","volume":"6","author":"Kirschner","year":"2014","journal-title":"WIREs Sys. Biol. Med."}],"updated-by":[{"DOI":"10.1016\/j.bbcan.2025.189268","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000}},{"DOI":"10.1016\/j.bbcan.2022.188727","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000}}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X2200052X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X2200052X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T13:08:53Z","timestamp":1735391333000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X2200052X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":191,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0304419X2200052X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2022.188727","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RETRACTED: Coagulation and inflammation in cancer: Limitations and prospects for treatment","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2022.188727","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"188727"}}